[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
about
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic AgentsPharmacodynamic Biomarker Development for PI3K Pathway TherapeuticsDevelopment of Companion DiagnosticsFirst-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.Mechanisms underlying 18F-fluorodeoxyglucose accumulation in colorectal cancerPhase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphomaIncreased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapyBiomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further ProposalsAnti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PETTherapeutic options for the management of pancreatic cancer.North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.Systematic analysis of 18F-FDG PET and metabolism, proliferation and hypoxia markers for classification of head and neck tumorsClinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancerA phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues.Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?Statins impair glucose uptake in tumor cellsAn Oncogenic Virus Promotes Cell Survival and Cellular Transformation by Suppressing GlycolysisEverolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.The Emerging Hallmarks of Cancer MetabolismUtility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.The role of fluorine-18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: an overviewPerifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer.FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.GLUT1 as a therapeutic target in hepatocellular carcinoma.Control of nutrient stress-induced metabolic reprogramming by PKCζ in tumorigenesis.Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.Conceptual framework for cutting the pancreatic cancer fuel supply.Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma.Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer.Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis.Metastatic Renal Cancer: What Role for Everolimus?Canonical and new generation anticancer drugs also target energy metabolism.FDG PET/CT imaging as a biomarker in lymphoma.Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.
P2860
Q26740567-02D76ED6-7A1C-4DE3-AA98-9F627BA4612FQ26766292-D013FBD7-1C45-4B83-8455-D5D453703548Q26774670-0F6E21A1-C0B3-4DE2-97B0-EEBF55456FD7Q27853088-81630CF3-884B-4391-81AC-8AF33BB48EDCQ28067736-5A485498-88DC-4C1F-8E55-785D1DEBAEA5Q33396217-9DE3433D-F128-4CCE-984E-6F2C48D348A2Q33706877-2557ACB7-83F5-438E-A7D2-8369F961611CQ33730033-C07BE1CA-689B-4FB9-B39E-DF804EC81A8AQ33760578-86A58CE8-450E-4A7A-A3AF-34855728817FQ34041370-89EC8B5A-D006-4F52-9426-E9A3FAF66EBDQ34093776-E59715C9-6FF9-4928-9D9A-197DFD750774Q34441838-A2FA6C6B-4295-4E40-B139-295A2470F9F9Q35103263-207B816B-828A-480A-8541-E53E5903E2CDQ35169825-AD749691-8958-4299-A1BD-4B75D022472EQ35567261-C2CF8DAA-714F-420F-92FC-F846B1D4C1E5Q35584486-B3E0B6C9-F76A-4269-AC0D-44356BCFFBBCQ35584938-9E5F8D4C-1853-496D-95E0-9DA7AED5E499Q35660948-BC3EB406-FEFC-4DA5-B4E8-DBAD21A168B0Q35879814-4DD0E498-C986-4922-95D6-85AE80E93E50Q35949773-53405267-FE44-43D0-B449-8F4F727264A0Q36019773-A3D800F1-1FD8-4679-AA29-7C1EE80804EAQ36200547-2040A37A-B705-4081-A0E8-E14B005D8C14Q36468964-026039BB-0D52-4AA6-91BD-850B570AC624Q36533822-465191F5-EF1A-4664-8466-2622BCB3EB5DQ36694518-322259C7-7B0B-4071-97FA-5D6984A287C0Q36801971-471EAFC1-CE5D-41A0-AECC-AF50D9C3A0B2Q37082453-99AB8089-6BE9-4794-B4D7-6796D7AA51D1Q37236032-A6D52E04-39BF-4471-BAED-3D649825F4ADQ37236275-6F517E77-B00C-416E-981A-176EC7C52231Q37623840-2240CA55-1907-4ADE-B513-13F30FEF55E1Q37659446-A3703534-EAC2-475C-B04E-6C98C87819F6Q37871915-BEEEDD3E-4B60-4F45-9C88-E595D1AD88ECQ38034956-9A1B724B-9530-4D8B-9638-19D94362202EQ38040684-195B30C1-2052-4D57-B330-22EE880C95B3Q38134094-29B6A27D-34C9-49F6-8DB5-BA14C26AFBCAQ38176862-1BDAF268-3F5A-47FE-B32B-CBF7CE3A0153Q38207580-3A2FA49D-1BDE-45D5-A21B-8C06926B1541Q38208982-80C24DBA-5DB6-429A-83F8-1FCA3E86ED38Q38312367-7F21F200-5103-4A17-AEE8-5547C5E1CDC7Q38737416-8817F125-47DF-4D8B-BB5E-1028C9A20034
P2860
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
[18F]fluorodeoxyglucose positr ...... during mTOR inhibitor therapy.
@en
[18F]fluorodeoxyglucose positr ...... during mTOR inhibitor therapy.
@nl
type
label
[18F]fluorodeoxyglucose positr ...... during mTOR inhibitor therapy.
@en
[18F]fluorodeoxyglucose positr ...... during mTOR inhibitor therapy.
@nl
prefLabel
[18F]fluorodeoxyglucose positr ...... during mTOR inhibitor therapy.
@en
[18F]fluorodeoxyglucose positr ...... during mTOR inhibitor therapy.
@nl
P2093
P2860
P356
P1476
[18F]fluorodeoxyglucose positr ...... during mTOR inhibitor therapy
@en
P2093
Antonio Jimeno
Chris Endres
Dan Laheru
Dongweon Song
Heather Jacene
Martin G Pomper
Richard Wahl
Wells A Messersmith
Wen Wee Ma
P2860
P304
P356
10.1200/JCO.2008.18.8383
P407
P577
2009-04-20T00:00:00Z